Seres Therapeutics (MCRB) Tops Q3 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Seres Therapeutics (MCRB) Tops Q3 EPS by 4c

Seres Therapeutics Reports Third Quarter 2016 Financial Results and Provides Operational Progress Update

November 10, 2016 7:30 AM EST

- Analyses of SER-109 Phase 2 results on track for completion by year end;
Company intends to discuss proposed future SER-109 clinical development plans with the FDA -

- Pipeline progress with SER-287 and SER-262 Phase 1b study execution;
data read-outs continue to be expected in 2017 -

- New microbiome patent strengthens the Companys intellectual property estate -

- Conference call at 8:00 a.m. ET today -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc., (NASDAQ:... More